BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 30453728)

  • 1. Development of Web-Based Nomograms to Predict Treatment Response and Prognosis of Epithelial Ovarian Cancer.
    Kim SI; Song M; Hwangbo S; Lee S; Cho U; Kim JH; Lee M; Kim HS; Chung HH; Suh DS; Park T; Song YS
    Cancer Res Treat; 2019 Jul; 51(3):1144-1155. PubMed ID: 30453728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pretreatment Complete Blood Cell Counts in Epithelial Ovarian Cancer.
    Paik ES; Sohn I; Baek SY; Shim M; Choi HJ; Kim TJ; Choi CH; Lee JW; Kim BG; Lee YY; Bae DS
    Cancer Res Treat; 2017 Jul; 49(3):635-642. PubMed ID: 27669704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and validation of nomograms for epithelial ovarian cancer: a SEER population-based, real-world study.
    Wang R; Xie G; Shang L; Qi C; Yang L; Huang L; Li D; Yang W
    Future Oncol; 2021 Mar; 17(8):893-906. PubMed ID: 33533669
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer.
    Chambers LM; Kuznicki M; Yao M; Chichura A; Gruner M; Reizes O; Debernardo R; Rose PG; Michener C; Vargas R
    Gynecol Oncol; 2020 Dec; 159(3):699-705. PubMed ID: 32950250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative albumin-to-fibrinogen ratio predicts chemotherapy resistance and prognosis in patients with advanced epithelial ovarian cancer.
    Yu W; Ye Z; Fang X; Jiang X; Jiang Y
    J Ovarian Res; 2019 Sep; 12(1):88. PubMed ID: 31533857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The relationship of preoperativelymphocyte-monocyte ratio and the clinicopathological characteristics and prognosis of patients with epithelial ovarian cancer].
    Yang HM; Lou G
    Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):676-680. PubMed ID: 28926896
    [No Abstract]   [Full Text] [Related]  

  • 7. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy.
    Miao Y; Yan Q; Li S; Li B; Feng Y
    Cancer Biomark; 2016 Jun; 17(1):33-40. PubMed ID: 27314290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
    Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J
    Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prediction of progression-free and overall survival in women with an advanced stage of epithelial ovarian carcinoma.
    Gerestein CG; Eijkemans MJ; de Jong D; van der Burg ME; Dykgraaf RH; Kooi GS; Baalbergen A; Burger CW; Ansink AC
    BJOG; 2009 Feb; 116(3):372-80. PubMed ID: 19187369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel nomogram based on LODDS to predict the prognosis of epithelial ovarian cancer.
    Xu XL; Cheng H; Tang MS; Zhang HL; Wu RY; Yu Y; Li X; Wang XM; Mai J; Yang CL; Jiao L; Li ZL; Zhong ZM; Deng R; Li JD; Zhu XF
    Oncotarget; 2017 Jan; 8(5):8120-8130. PubMed ID: 28042955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment and verification of the nomogram that predicts the 3-year recurrence risk of epithelial ovarian carcinoma.
    Hu J; Jiao X; Zhu L; Guo H; Wu Y
    BMC Cancer; 2020 Sep; 20(1):938. PubMed ID: 32993522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Significance of Preoperative Prognostic Nutritional Index in Epithelial Ovarian Cancer Patients Treated with Platinum-Based Chemotherapy.
    Miao Y; Li S; Yan Q; Li B; Feng Y
    Oncol Res Treat; 2016; 39(11):712-719. PubMed ID: 27855385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
    Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
    Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutrophil-to-Lymphocyte Ratio and Platelet Count Predict Long-Term Outcome of Stage IIIC Epithelial Ovarian Cancer.
    Zhou M; Li L; Wang X; Wang C; Wang D
    Cell Physiol Biochem; 2018; 46(1):178-186. PubMed ID: 29587273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical impact of high mobility group box 1 protein in epithelial ovarian cancer.
    Paek J; Lee M; Nam EJ; Kim SW; Kim YT
    Arch Gynecol Obstet; 2016 Mar; 293(3):645-50. PubMed ID: 26305032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum CA125 levels predict outcome of interval debulking surgery after neoadjuvant chemotherapy in patients with advanced ovarian cancer.
    Zhang D; Jiang YX; Luo SJ; Zhou R; Jiang QX; Linghu H
    Clin Chim Acta; 2018 Sep; 484():32-35. PubMed ID: 29702068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and internal validation of a prognostic model for survival after debulking surgery for epithelial ovarian cancer.
    Rutten MJ; Boldingh JH; Schuit E; Trum H; van Driel W; Mol BW; Kenter GG; Buist MR
    Gynecol Oncol; 2014 Oct; 135(1):13-8. PubMed ID: 25093289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer.
    Manzanedo I; Pereira F; Pérez-Viejo E; Serrano Á; Hernández-García M; Martínez-Torres B; Rihuete-Caro C; Calzas J; Cueto M
    Minerva Ginecol; 2017 Apr; 69(2):119-127. PubMed ID: 27415829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy.
    Previs RA; Bevis KS; Huh W; Tillmanns T; Perry L; Moore K; Chapman J; McClung C; Kiet T; Java J; Chan J; Secord AA
    Gynecol Oncol; 2014 Mar; 132(3):531-6. PubMed ID: 24472410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
    Bian C; Yao K; Li L; Yi T; Zhao X
    Arch Gynecol Obstet; 2016 Jan; 293(1):163-168. PubMed ID: 26198168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.